Modulation of Beta-amyloid Levels in CSF and Plasma by GSK933776 in Patients With Mild Alzheimer's Disease or Mild Cognitive Impairment.
Phase of Trial: Phase I
Latest Information Update: 16 Jun 2017
At a glance
- Drugs GSK 933776 (Primary)
- Indications Alzheimer's disease
- Focus Pharmacodynamics
- 16 Jun 2017 Last checked against ClinicalTrials.gov record.
- 10 Jun 2017 Biomarkers information updated
- 18 May 2012 Actual patient number added 19 according to ClinicalTrials.gov.